

# Texas Department of State Health Services

## Seasonal Flu, New ACIP Recommendations, and Vaccine Supply Updates

November 5<sup>th</sup>, 2009



[www.ImmunizeTexas.com](http://www.ImmunizeTexas.com)



# *2009-2010 Flu Season*



# ACIP Recommendations for Prevention and Control of Influenza (2009-2010 influenza season):

In July, 2009, the ACIP made policy recommendations for use of influenza vaccine for the 2009-2010 influenza season.

- The 2009–2010 trivalent influenza vaccines will contain A/Brisbane/59/2007 (H1N1)-like, A/Brisbane/10/2007 (H3N2)-like, and B/Brisbane/60/2008-like antigens. Compared to the 2008-09 Northern Hemisphere influenza vaccines, only the B strain has changed.
- Age and risk groups previously recommended for annual vaccination against influenza have not changed.
- All children aged 6 months through 18 years are recommended to receive vaccination against influenza for the 2009-2010 influenza season.

# Seasonal Flu Doses Manufactured (2005-2009)



Original Estimated overall production in 2009-2010: 118 M

# CDC Doses Available For VFC Programs (2009-2010)

CDC had 11,438,374 doses allocated to states

- ~10% of total flu vaccine produced
- ~80 % of doses have been allocated/shipped to states as of 11/4/2009 to fill VFC provider orders
- Remaining 20% due for delivery during November and early December
- Preservative-free and infant-toddler doses formulations included in early releases

# Texas DSHS Flu Doses Ordered for TVFC 2008-2009

Formulation	2009	2008
.25 mL doses:	355,930	293,960
Flumist®	297,270	105,810
.5 mL doses:	439,120	459,652
<b>TOTAL</b>	<b>1,092,320</b>	<b>859,422</b>

Texas had a pending second round allocation of 37,610 additional doses

Total Tx VFC Pop (2009): +3,900,000  
Total Tx VFC Doses (2009): 1,129,930

# Summary

- Influenza Vaccine Availability Tracking System (IVATS), provides information about vaccine manufacturers and distributors with vaccine available for purchase. IVATS can be found at: <http://www.preventinfluenza.org/ivats/>
- Most providers were able to obtain vaccine from their usual provider, but some will have to obtain the vaccine from an alternative provider
- People can find seasonal vaccine by checking the American Lung Association web site that identifies clinics that have influenza vaccine available: <http://www.flucliniclocator.org/>
- We are still early in flu season; there is still time for people to get vaccinated to protect them from becoming ill.

# Newly Licensed and Upcoming Vaccine Update

## Recently Licensed Vaccines

- Hib (GSK)- Hiberix: booster vaccine licensed for only 4<sup>th</sup> dose (9/19/2009)
- H1N1 (5 manufacturers)- Pandemic Flu Vaccine
- HPV (GSK)- Cervarix™: bivalent vaccine

## Upcoming Vaccines (2009-2010)

- Meningococcal (Novartis)- Similar to MCV4 with same adolescent recommendations (4<sup>th</sup> Qtr./2009)
- PCV 13 (Wyeth)- 6 additional serotypes than PCV7 (4<sup>th</sup> Qtr./2009)
- Meningococcal/Hib (GSK)- 4 dose meningococcal and Hib vaccine targeting infants at 2, 4, 6, and 12-15 month (early/mid 2010)

# *ACIP Meeting Update*

<http://www.cdc.gov/vaccines/recs/acip/slides-oct09.htm#hpv>



# ACIP Meeting Summary

## (10/21/09-10/22/09)

- Human Papillomavirus Vaccine (2 issues)
  - Quadrivalent (types 6,11, 16, 18) HPV4 for males
    - Merck Product (Gardasil)
    - Licensed for females in 2006 (9-26 year olds)
    - Licensed for males (9-26 years of age) for prevention of HPV 6 and HPV 11 related to genital warts
      - Permissive recommendation for males
  - Bivalent (types 16 and 18) HPV2 for females
    - GSK Product (Cervarix™)
    - Licensed for females 10-25 years of age

# Affirmative and Permissive Recommendation

Action	Affirmative recommendation	Permissive recommendation
Provider expected to offer vaccine proactively to VFC-eligible child	Yes	No
Provider expected to vaccinate VFC-eligible child on request	Yes	Yes, if provider stocks vaccine, else refer
Provider may offer vaccine proactively to VFC-eligible child	Yes	Yes
Immunization programs expected to promote recommendation	Yes	No
Uptake is measure of program or provider performance	Yes	No

A Permissive Resolution is not a mandate on children, parents, providers or programs

# ACIP Meeting Summary

## (10/21/09-10/22/09)

- Human Papillomavirus Vaccines
  - Interchangeability: “ACIP recommends that the HPV vaccines series be completed with the same HPV vaccine product whenever possible. However, if vaccination providers do not know or have available the HPV vaccine product previously administered, either HPV vaccine product can be used to continue or complete the series to provide protection against HPV 16 and 18.”
  - The dosing schedule is the same for both vaccines: 3-dose schedule, second dose 1 to 2 months after first dose and third dose 6 months after the first dose.

# ACIP Meeting Summary

## (10/21/09-10/22/09)

- 2010 Childhood and Adolescent Schedules
  - ACIP will review changes to the 2010 childhood and adolescent immunization schedules. These include: 0-6 years of age, 7-18 years of age, and catch-up schedule for children 4 months through 18 years of age
  - Proposed changes include
    - Update on rotavirus footnote
    - Addition of Hiberix (FDA licensed 8/2009) to schedule
    - Hepatitis A footnote to allow for vaccination of children “for whom immunity is desired:
    - Meningococcal footnotes updated

# ACIP Meeting Summary

## (10/21/09-10/22/09)

- 2010 Adult Schedule
  - ACIP will review changes to the 2010 adult immunization schedule.
    - First released in 2002
    - HPV proposed update: addition of HPV2 (for females 19-26) and new indication for HPV4 for males 19-26)
    - Influenza footnote proposed to add the term seasonal flu (clarify between seasonal and pandemic)
    - Proposal for indications for revaccination of meningococcal vaccine (MCV4) for high-risk adults

# ACIP Meeting Summary

## (10/21/09-10/22/09)

- Meningococcal Conjugate Vaccine
  - License of combined HibMenCY vaccine for infants within next 6-9 months anticipated
    - 4 dose series (2m, 4m, 6m, 12-15 m)
    - Approx. 80-100 cases and 4-8 deaths may be prevented with routine vaccines in infants
  - Currently, ACIP is considering not recommending routine vaccination with MCV in infants at this time, but will continue to follow disease rates. Will revisit this decision at 6/2010 ACIP meeting.

# ACIP Meeting Summary

## (10/21/09-10/22/09)

- Pneumococcal Vaccines – PCV 13
  - New 13 valent pneumococcal conjugate vaccine (PCV 13) is expected to be reviewed by FDA in December, 2009
    - Manufactured by Wyeth
    - Protection against 6 additional serotypes not contained in current PCV 7 vaccine
    - Proposed schedule is same for PCV 13 as is current PCV 7 (2m, 4m, 6m 12-15m)
    - PCV 13 will be interchangeable with PCV 7 (for transition period) for completion of series

# Vaccine Supply Update

- Hib Vaccine
  - 3 Hib containing vaccines now available (Pentacel, ActHib, and Hiberix)
    - Hiberix has 4<sup>th</sup> dose indication only
  - CDC (MMWR 10/18/2009) announced with the licensure of new vaccine and additional doses from the current supply make possible the recommendation to encourage broad catch up, including mass recall
  - Merck's monovalent vaccine expected to be fully available in 1<sup>st</sup> quarter of 2010

# Vaccine Supply Update

- Hepatitis B – Pediatric
  - Since 3/2009, vaccine supply has been managed due to limited vaccine availability
  - Merck expects to have full supply available beginning 1<sup>st</sup> quarter, 2010 to help with inventory levels
- Hepatitis B – Adult
  - Some delays due to only one manufacturer having product available (2 – 4 week)
  - Additional supply anticipated in 1<sup>st</sup> quarter, 2010

# Vaccine Supply Update

- Hepatitis A – Pediatric
  - Recently, supply has been delayed but doses are/have been available
  - Both manufacturers are currently producing vaccine; anticipated full supply by 1<sup>st</sup> quarter, 2010
- Hepatitis A – Adult
  - GSK only supplier of vaccine at this time (in both monovalent and combination Hep A/Hep B vaccine)
  - Minimal delays